C12Y 304/21027
Coagulation factor xia
Official title: Coagulation factor XIa (3.4.21.27)
C12Y304/21027 (Coagulation factor xia) appears on 34 US grants and 82 published applications in this corpus.
Search patents in C12Y- Granted patents
- 34
- Published applications
- 82
- Assignees
- 30
- Inventors
- 99
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 4 |
| 2011 | 0 | 0 |
| 2012 | 2 | 1 |
| 2013 | 0 | 4 |
| 2014 | 1 | 28 |
| 2015 | 10 | 2 |
| 2016 | 2 | 4 |
| 2017 | 2 | 5 |
| 2018 | 0 | 3 |
| 2019 | 3 | 3 |
| 2020 | 4 | 4 |
| 2021 | 2 | 7 |
| 2022 | 1 | 3 |
| 2023 | 1 | 4 |
| 2024 | 1 | 2 |
| 2025 | 2 | 4 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- High-activity blood coagulation factor XI mutant Ala570Thr21 Apr 2026US 12,605,430 B2Ruijin Hospital Shanghai Jiaotong University School of Medicine
- Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use16 Dec 2025US 12,497,622 B2Suzhou Ribo Life Science Co., Ltd.
- Oligomeric compound for inhibiting expression of factor XI5 Aug 2025US 12,378,552 B2Sirnaomics, Inc.
- Methods for preparing and using highly active blood coagulation factor XI mutant and gene therapy/editing vector and recombinant/fusion protein thereof27 Feb 2024US 11,913,042 B2Ruijin Hospital Shanghai Jiaotong University School of Medicine
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins31 Jan 2023US 11,564,998 B2ModernaTX, Inc.
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
- Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use2 Apr 2026US 2026/0092280 A1Suzhou Ribo Life Science Co., Ltd.
- Galnac monomer comprising ribose ring or derivative structure thereof and use thereof in liver-targeted delivery of small nucleic acid drugs26 Mar 2026US 2026/0085320 A1Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
- Compositions and methods for treating heart failure13 Nov 2025US 2025/0345404 A1The Regents of the University of California
- Polynucleic acid molecules for inhibiting expression of fxi, pharmaceutical compositions, and uses thereof7 Aug 2025US 2025/0250573 A1Sirius Therapeutics, Inc.
Most cited
By later US patents
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1124US 9,095,552 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding citeD4124US 9,114,113 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating galactosylceramidase protein deficiency121US 9,089,604 B2Moderna Therapeutics, Inc. · 2015